Treatment patterns for metastatic colorectal cancer in Spain

[1]  J. Aparicio,et al.  SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer (2018) , 2018, Clinical and Translational Oncology.

[2]  H. Ali,et al.  Institutional adherence to National Comprehensive Cancer Network (NCCN) guidelines in neoadjuvant treatment of breast cancer and its correlation to outcomes. , 2018, Journal of Clinical Oncology.

[3]  Xianglin L. Du,et al.  Adherence to treatment guidelines and survival for older patients with stage II or III colon cancer in Texas from 2001 through 2011 , 2018, Cancer.

[4]  M. V. van Oijen,et al.  Evaluation of Guideline Adherence in Colorectal Cancer Treatment in The Netherlands: A Survey Among Medical Oncologists by the Dutch Colorectal Cancer Group , 2017, Clinical colorectal cancer.

[5]  A. Rajput,et al.  KRAS biomarker testing disparities in colorectal cancer patients in New Mexico , 2017, Heliyon.

[6]  S. Vinod,et al.  Assessing guideline adherence and patient outcomes in cervical cancer , 2017, Asia-Pacific journal of clinical oncology.

[7]  D. West,et al.  KRAS testing and first-line treatment among patients diagnosed with metastatic colorectal cancer using population data from ten National Program of Cancer Registries in the United States. , 2017, Journal of cancer research & therapy.

[8]  M. Fakih,et al.  RAS and BRAF in metastatic colorectal cancer management. , 2016, Journal of gastrointestinal oncology.

[9]  H. Dosaka-akita,et al.  Role of targeted therapy in metastatic colorectal cancer , 2016, World journal of gastrointestinal oncology.

[10]  J. Aparicio,et al.  Equity, barriers and cancer disparities: study of the Spanish Society of Medical Oncology on the access to oncologic drugs in the Spanish Regions , 2016, Clinical and Translational Oncology.

[11]  J Ricke,et al.  ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  Ahmedin Jemal,et al.  Global patterns and trends in colorectal cancer incidence and mortality , 2016, Gut.

[13]  R. Salazar,et al.  SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer 2015 , 2015, Clinical and Translational Oncology.

[14]  E. Dequeker,et al.  External quality assessment unravels interlaboratory differences in quality of RAS testing for anti-EGFR therapy in colorectal cancer. , 2015, The oncologist.

[15]  B. Glimelius,et al.  A population-based cohort study on adherence to practice guidelines for adjuvant chemotherapy in colorectal cancer , 2014, BMC Cancer.

[16]  E. Van Cutsem,et al.  Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  I. Oyagüez,et al.  Análisis de patrones de tratamiento y coste farmacológico en pacientes con cáncer colorrectal metastásico en un hospital general , 2014 .

[18]  J. Meyerhardt,et al.  Chemotherapy usage patterns in a US-wide cohort of patients with metastatic colorectal cancer. , 2014, Journal of the National Cancer Institute.

[19]  A. Haynes,et al.  Association between adherence to National Comprehensive Cancer Network treatment guidelines and improved survival in patients with colon cancer , 2013, Cancer.

[20]  R. Labianca,et al.  ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  J. Renaud-salis,et al.  Quality indicators for colorectal cancer surgery and care according to patient-, tumor-, and hospital-related factors , 2012, BMC Cancer.

[22]  M. Bhosle,et al.  Patterns of treatment with chemotherapy and monoclonal antibodies for metastatic colorectal cancer in Western Europe , 2012, Current medical research and opinion.

[23]  H. Kennecke,et al.  Impact of irinotecan and oxaliplatin on overall survival in patients with metastatic colorectal cancer: a population-based study. , 2007, Journal of oncology practice.

[24]  D. Belchis,et al.  Aberrant NHERF1 expression as a biomarker in lung carcinoma , 2016 .

[25]  S. Greenfield,et al.  Clinical practice guidelines we can trust , 2011 .